FDA requires warning about rare vision-loss risk for GLP-1 medications

November 13th, 20260 WASHINGTON, D.C. — The U.S. Food and Drug Administration has issued a new safety warning for GLP-1 medications used to treat type 2 diabetes and manage weight, requiring manufacturers to add information about a potential increased risk of a rare eye condition that can cause sudden vision loss. The November 9 announcement concerns...